Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,569 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel; Combination Product · Biological · Drug
Lead sponsor: Rakuten Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 5 more

Conditions: Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions: Acalabrutinib, Investigator's choice of treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Pediatrics, Medically Complex, Children With Medical Complexity (CMC), Nursing
Interventions: CHAMP App; Device
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Bryant, Arkansas • Fountain Valley, California • Los Angeles, California + 22 more

Conditions: Schizophrenia
Interventions: PF 03654746, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypoalbuminemia
Interventions: Specimen collection; Procedure
Lead sponsor: Akron Children's Hospital; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Mantua, Ohio

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Kidney Transplantation, Diabetes, Hyperglycemia
Interventions: insulin, NPH Insulin or glargine insulin and aspartame insulin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypertension
Interventions: Omada Hypertension Program; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab 1, Tozorakimab 2, Placebo; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 46
States / cities: Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more

Conditions: Coronavirus (SARS-CoV)
Interventions: Aluminum hydroxide, Placebo, SARS-CoV; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease Vaso-occlusive Crisis
Interventions: CSL889, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more

Conditions: Parkinsons Disease, Sleep
Interventions: Osteopathic Manipulative Treatment, Sham (No Treatment); Procedure
Lead sponsor: New York Institute of Technology; Other
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions: monoclonal antibody SGN-30, placebo, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ANCA-Associated Vasculitis
Interventions: Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 41
States / cities: Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more

Conditions: Infection, Bone Neoplasms
Interventions: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen; Drug
Lead sponsor: McMaster University; Other
Eligibility: 12 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 34
States / cities: Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 26 more

Conditions: Radius Fracture Distal, Pain, Postoperative
Interventions: Acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions: CMP-001, Nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine; Drug · Biological
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more

Conditions: Diabetic Retinopathy
Interventions: Surabgene Lomparvovec, Sham, Topical Steroid, Artificial Tears; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 39
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 36 more

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: CPG 7909, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 17
States / cities: Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Ibuprofen 400 mg, Acetaminophen 650 mg, OxyCODONE 5 Mg Oral Tablet; Drug
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Parental Adherence of a Mobile Application

Treatment of Alcohol Dependence and Comorbid Bipolar Disorder

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Add On Treatment for Cognitive Deficits in Schizophrenia

Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

IV Insulin Protocol in Diabetes and Renal Transplantation

Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

SARS Coronavirus Vaccine (SARS-CoV)

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Effects of Osteopathic Manipulative Treatment Protocol on Sleep Quality in Parkinson's Disease Subjects

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

Auricular Acupuncture As Part Of A Multimodal Regimen After Distal Radius Open Reduction and Internal Fixation

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

CPG 7909 Injection in Non-Small Cell Lung Cancer

Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis